Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies, University of Melbourne Partner on Breast Cancer Risk Test

NEW YORK (GenomeWeb) – Australian molecular diagnostics firm Genetic Technologies announced today that it has partnered with the University of Melbourne to broaden the applicability of its BrevaGenplus breast cancer risk assessment test.

Genetic Technologies' BrevaGenplus is currently designed for women aged 35 years or older who have not had breast cancer but who have one or more risk factors. In collaboration with the University of Melbourne, the company is aiming to expand the test's use to women with an extended family history of the disease, and increase the range of risk factors analyzed by the test.

Additional terms of the deal were not disclosed.

In addition to BrevaGenplus, Genetic Technologies is developing a colorectal cancer risk assessment test. The company also recently partnered with Omix Ventures to develop and access a blockchain-based global genomic data management platform for cancer diagnostic development.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.